AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25492264 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Enhanced Videofeedback Engagement (CEVE) intervention
Number of subjects: 19
Study 25492264 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 19
Study 22645023 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus delbrueckii subsp. bulgaricus 8481), 3 capsules per day for 6 months
Number of subjects: 61
Study 22645023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 22046862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 80
Study 22046862 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 80
Study 19609623 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic discharge summary (EDS)
Number of subjects: 209
Study 19609623 — intervention group
Group type: COMPARATOR
Intervention: Conventional dictated discharge summaries
Number of subjects: 209
Study 16469992 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) at doses of 1.35, 2.7, or 4.05 g/d for 12 weeks
Number of subjects: 0
Study 16469992 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 0
Study 16469992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 0
Study 15592577 — intervention group
Group type: EXPERIMENTAL
Intervention: Monteplase followed by PCI
Number of subjects: 0
Study 15592577 — intervention group
Group type: COMPARATOR
Intervention: Direct PCI without monteplase
Number of subjects: 0
Study 15592577 — intervention group
Group type: EXPERIMENTAL
Intervention: Monteplase + PCI
Number of subjects: 0
Study 15483809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential method including individual pressurization of each anchorage hole
Number of subjects: 0
Study 15483809 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressurizer
Number of subjects: 0
Study 10027359 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 500
Study 10027359 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 500
Study 7850048 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefoxitin intravenously (n = 78)
Number of subjects: 153
Study 7850048 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (n = 75)
Number of subjects: 153
Study 2390921 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II anastomosis
Number of subjects: 22
Study 2390921 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y anastomosis
Number of subjects: 22
Study 2390921 — intervention group
Group type: COMPARATOR
Intervention: Both Billroth II and Roux-en-Y anastomosis
Number of subjects: 22
Study 489517 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 40
Study 489517 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study 31915058 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 66
Study 31915058 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stenting
Number of subjects: 66
Study 31915058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial and extra‐cranial bypass
Number of subjects: 66
Study 31915058 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 66
Study 31462629 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% orange juice with 5 g of enzyme-treated orange pomace fiber (OPF)
Number of subjects: 10
Study 31462629 — intervention group
Group type: COMPARATOR
Intervention: 100% orange juice (OJ)
Number of subjects: 10
Study 31462629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OPF juice and OJ
Number of subjects: 10
Study 28815987 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin plus diet and exercise
Number of subjects: 5624
Study 28815987 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 5624
Study 28815987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5624
Study 25598270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary folate equivalent
Number of subjects: 141
Study 25598270 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA)
Number of subjects: 141
Study 25598270 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) in individuals with CC genotype for MTHFR C677T variant
Number of subjects: 141
Study 24638046 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-SR plus escitalopram
Number of subjects: 567
Study 24638046 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR plus mirtazapine
Number of subjects: 567
Study 24638046 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram plus placebo
Number of subjects: 567
Study 24638046 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatments
Number of subjects: 567
Study 24638046 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 567
Study 22971486 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous approach
Number of subjects: 61
Study 22971486 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal approach
Number of subjects: 61
Study 22971486 — intervention group
Group type: COMPARATOR
Intervention: Both approaches
Number of subjects: 61
Study 19778774 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel‐eluting stent (PES)
Number of subjects: 80
Study 19778774 — intervention group
Group type: COMPARATOR
Intervention: Bare‐metal stent (BMS)
Number of subjects: 80
Study 18080228 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical or systemic corticosteroids
Number of subjects: 0
Study 18080228 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonists (montelukast)
Number of subjects: 0
Study 18080228 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5 blockers (Mepolizumab)
Number of subjects: 0
Study 18080228 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougies or balloon dilation
Number of subjects: 0
Study 18080228 — intervention group
Group type: COMPARATOR
Intervention: Anti-inflammatory agents
Number of subjects: 0
Study 15046934 — intervention group
Group type: EXPERIMENTAL
Intervention: Index TKA
Number of subjects: 60
Study 15046934 — intervention group
Group type: COMPARATOR
Intervention: Revision TKA
Number of subjects: 60
Study 15046934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 12653168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried hazelnut (1 mg to 1 g hazelnut protein)
Number of subjects: 31
Study 12653168 — intervention group
Group type: COMPARATOR
Intervention: Placebo doses
Number of subjects: 31
Study 9520230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain site measurement
Number of subjects: 28
Study 9520230 — intervention group
Group type: COMPARATOR
Intervention: Control site measurement
Number of subjects: 28
Study 9520230 — intervention group
Group type: COMPARATOR
Intervention: Examiner's knowledge manipulation
Number of subjects: 28
Study 7927488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms nasal spray twice daily for 6 weeks
Number of subjects: 48
Study 7927488 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 48
Study 7927488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 48
Study 2582771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 75 micrograms gestodene
Number of subjects: 6
Study 2582771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 25 micrograms gestodene
Number of subjects: 6
Study 2582771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 75 micrograms gestodene
Number of subjects: 6
Study 2582771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 125 micrograms gestodene
Number of subjects: 6
Study 31489425 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control circle guided nursing
Number of subjects: 120
Study 31489425 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 120
Study 28161559 — intervention group
Group type: EXPERIMENTAL
Intervention: Commentary exposure
Number of subjects: 0
Study 28161559 — intervention group
Group type: COMPARATOR
Intervention: Live commentary production
Number of subjects: 0
Study 28161559 — intervention group
Group type: COMPARATOR
Intervention: Commentary unexposed group
Number of subjects: 0
Study 26482128 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic rapid screen-and-treat program using a point-of-care analysis with molecular quantification method
Number of subjects: 6800
Study 26482128 — intervention group
Group type: COMPARATOR
Intervention: Usual care management
Number of subjects: 6800
Study 26482128 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic rapid screen-and-treat program
Number of subjects: 6800
Study 23603887 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg) plus dexamethasone (4 mg IV)
Number of subjects: 0
Study 23603887 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dexamethasone (4 mg IV)
Number of subjects: 0
Study 21908768 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of HPV16/18 vaccine (Cervarix)
Number of subjects: 5967
Study 21908768 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HPV16/18 vaccine (Cervarix)
Number of subjects: 5967
Study 21908768 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of HPV16/18 vaccine (Cervarix)
Number of subjects: 5967
Study 19552598 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg/d)
Number of subjects: 55
Study 17349072 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (CEE; 0.625 mg/d)
Number of subjects: 13
Study 17349072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15367255 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐6D
Number of subjects: 331
Study 15367255 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI3
Number of subjects: 331
Study 15367255 — intervention group
Group type: COMPARATOR
Intervention: Both measures
Number of subjects: 331
Study 11808063 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% aqueous extract of freshly prepared miswak solution
Number of subjects: 12
Study 11808063 — intervention group
Group type: EXPERIMENTAL
Intervention: Soaking in miswak extract
Number of subjects: 12
Study 9670874 — intervention group
Group type: EXPERIMENTAL
Intervention: The Knack (pelvic muscle precontraction)
Number of subjects: 27
Study 7846263 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with radiotherapy to the primary tumor and CNS
Number of subjects: 57
Study 7846263 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 57
Study 2899090 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (22 mU/m2.min)
Number of subjects: 12
Study 2899090 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with SRIH (250 micrograms/h) and glucagon (0.4 ng/kg.min)
Number of subjects: 12
Study 30523464 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Ponseti technique (cast change interval of 3 days)
Number of subjects: 0
Study 30523464 — intervention group
Group type: COMPARATOR
Intervention: Standard Ponseti technique (cast change interval of 7 days)
Number of subjects: 0
Study 28190980 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (0.03 g.kg.d‐1 during 14 d)
Number of subjects: 19
Study 28190980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 24990422 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP variability (measured as coefficient of variability)
Number of subjects: 2501
Study 24990422 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 2501
Study 24990422 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion for cerebrovascular disease
Number of subjects: 2501
Study 24990422 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model with BP variability
Number of subjects: 2501
Study 22496276 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric, normoproteic Mediterranean diet (MeD)
Number of subjects: 45
Study 22496276 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric, normoproteic Mediterranean diet plus periodized moderate-to-high intensity training (MeDE)
Number of subjects: 45
Study 21736762 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus educational materials
Number of subjects: 0
Study 21736762 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus educational materials and social worker intervention
Number of subjects: 0
Study 21736762 — intervention group
Group type: COMPARATOR
Intervention: Usual care by nephrologists
Number of subjects: 0
Study 17270519 — intervention group
Group type: EXPERIMENTAL
Intervention: Microprocessor control prosthetic knee (Otto Bock C-Leg)
Number of subjects: 21
Study 16276705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (Group A)
Number of subjects: 59
Study 16276705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized furosemide (Group B)
Number of subjects: 59
Study 16276705 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nebulized albuterol and furosemide (Group C)
Number of subjects: 59
Study 12045535 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (600 U/kg) weekly for 3 weeks
Number of subjects: 29
Study 12045535 — intervention group
Group type: COMPARATOR
Intervention: Control group (no erythropoietin)
Number of subjects: 29
Study 9928551 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8577886 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (5, 10 mg/70 kg, BID)
Number of subjects: 6
Study 8577886 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (30 mg/70 kg in four doses)
Number of subjects: 6
Study 8577886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2243148 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine
Number of subjects: 29
Study 2243148 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nifedipine
Number of subjects: 29
Study 2243148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 946844 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV‐77 DE‐5
Number of subjects: 5153
Study 946844 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV‐77 DK‐12
Number of subjects: 5153
Study 946844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cendehill
Number of subjects: 5153
Study 946844 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 5153
Study 29667330 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitors (TNFI)
Number of subjects: 6712
Study 29667330 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-TNF inhibitors (non-TNFI)
Number of subjects: 6712
Study 29667330 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids ≥ 5 mg/day
Number of subjects: 6712
Study 29667330 — intervention group
Group type: COMPARATOR
Intervention: Non-RA group
Number of subjects: 6712
Study 25787780 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake (two glasses of red wine, 12% ethanol)
Number of subjects: 18
Study 25787780 — intervention group
Group type: COMPARATOR
Intervention: Control day (no alcohol)
Number of subjects: 18
Study 25111667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized combination of salbutamol 1.875 mg/0.5 mL and ipratropium bromide 0.375 mg/0.5 mL
Number of subjects: 92
Study 25111667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 22401327 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced lipid suppression
Number of subjects: 23
Study 22401327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of Intralipid
Number of subjects: 23
Study 22401327 — intervention group
Group type: EXPERIMENTAL
Intervention: Common prediction model using a maximum of 10 gases
Number of subjects: 23
Study 20429383 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser tonsillectomy
Number of subjects: 102
Study 20429383 — intervention group
Group type: COMPARATOR
Intervention: Routine method (control group)
Number of subjects: 102
Study 18729835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 0
Study 18729835 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril
Number of subjects: 0
Study 18729835 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 18729835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0
Study 15856409 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW (Esbericum capsules; 240 mg/die of extract, 3.5 mg hyperforin)
Number of subjects: 28
Study 15856409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 14585254 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-Loop Stimulation (CLS)
Number of subjects: 149
Study 14585254 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD+ overdrive pacing
Number of subjects: 149
Study 14585254 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 149
Study 11104879 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-Seal device
Number of subjects: 150
Study 11104879 — intervention group
Group type: COMPARATOR
Intervention: FemoStop device
Number of subjects: 150
Study 8967858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleolar organizer (NO) activity in high-grade malignancy lymphomas
Number of subjects: 51
Study 8967858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleolar organizer (NO) activity in low-grade malignancy lymphomas
Number of subjects: 51
Study 8967858 — intervention group
Group type: COMPARATOR
Intervention: Nucleolar organizer (NO) activity in reactive follicular hyperplasia
Number of subjects: 51
Study 1559951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Low-Volume Taper (HIT)
Number of subjects: 9
Study 1559951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Moderate-Volume Taper (LIT)
Number of subjects: 9
Study 1559951 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-Only Taper (ROT)
Number of subjects: 9
Study 3901772 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.00 D add treatment
Number of subjects: 213
Study 3901772 — intervention group
Group type: EXPERIMENTAL
Intervention: +2.00 D add treatment
Number of subjects: 213
Study 3901772 — intervention group
Group type: COMPARATOR
Intervention: Single vision (standard treatment)
Number of subjects: 213
Study 29771161 — intervention group
Group type: EXPERIMENTAL
Intervention: Single below-knee cast (n = 10)
Number of subjects: 20
Study 29771161 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 serial casts (n = 10)
Number of subjects: 20
Study 29455211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD) administered once weekly for 4 consecutive weeks
Number of subjects: 37
Study 29455211 — intervention group
Group type: COMPARATOR
Intervention: Oral medication
Number of subjects: 37
Study 26293380 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fludarabine with darbepoetin alfa
Number of subjects: 97
Study 26293380 — intervention group
Group type: COMPARATOR
Intervention: Low-dose fludarabine without darbepoetin alfa
Number of subjects: 97
Study 26293380 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 97
Study 26293380 — intervention group
Group type: COMPARATOR
Intervention: Chemoimmunotherapy
Number of subjects: 97
Study 25239603 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethobenzamide
Number of subjects: 182
Study 25239603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 21566199 — intervention group
Group type: EXPERIMENTAL
Intervention: R1663 (oral factor Xa inhibitor)
Number of subjects: 33
Study 21566199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 20645031 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine adjunctive manual thrombectomy devices
Number of subjects: 0
Study 20645031 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger manual thrombectomy devices (7F) or mechanical devices
Number of subjects: 0
Study 17403494 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents
Number of subjects: 829
Study 17403494 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents with higher education levels
Number of subjects: 829
Study 17403494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers
Number of subjects: 829
Study 17403494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers
Number of subjects: 829
Study 17403494 — intervention group
Group type: COMPARATOR
Intervention: Parental socioeconomic level
Number of subjects: 829
Study 16259540 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 or 20 mg/day)
Number of subjects: 371
Study 16259540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 12100180 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% niacinamide moisturizer
Number of subjects: 138
Study 12100180 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% niacinamide + sunscreen
Number of subjects: 138
Study 12100180 — intervention group
Group type: COMPARATOR
Intervention: vehicle moisturizer
Number of subjects: 138
Study 12100180 — intervention group
Group type: COMPARATOR
Intervention: sunscreen
Number of subjects: 138
Study 10492259 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg, twice-daily)
Number of subjects: 408
Study 10492259 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 408
Study 10492259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 8619468 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal laparoscopic approach
Number of subjects: 120
Study 1793366 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (3 mg twice daily for 12 weeks)
Number of subjects: 25
Study 1793366 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo (3 mg twice daily for 12 weeks)
Number of subjects: 25
Study 6131066 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 53